deCODE launches scans for CVD and cancer risk

Through deCODEme, its retail genome analysis service, Iceland's deCODE genetics has launched the first focused genetic scans for assessing  personal risk of several major cardiovascular diseases and common  cancers.

deCODEme Cardio detects risk factors for heart attack, stroke and atrial  fibrillation, peripheral artery disease and several other conditions it  is available at an introductory price of $195. deCODEme Cancer measures  genetic risk factors for prostate, lung, bladder, skin and colorectal  cancers, as well as the common form of breast cancer, and is on sale  for $225. Both can be ordered as a bundle for $350.

deCODEme Cardio measures eight single-nucleotide polymorphisms  associated with the risk of heart attack, intracranical and abdominal  aortic aneurysm, stroke and atrial fibrillation, peripheral arterial  disease and venous thromboembolism. deCODEme Cancer measures 29 SNPs  associated with risk of various cancers, as well as basal cell carcinoma  and the common form of breast cancer. Based upon which versions of these  SNPs they carry, subscribers will receive a secure, on-line profile  presenting their results, both in terms of relative risk compared to the  general population, as well as absolute lifetime risk.